Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Stocks Nudge Higher, Nvidia AI Deal, Walgreens Boots Earnings, Eli Lilly Obesity Drug, Lordstown Bankruptcy - 5 Things To Know

Stock nudge higher on China stimulus hints; Nvidia shares gain on Snowflake AI partnership; Walgreens Boots Q3 earnings on deck; Eli Lilly jumps after solid data from 'Triple G' obesity treatment and Lordstown files for bankruptcy, sues Taiwan's Foxconn.

The Street

Weight-loss jab rejected for NHS use by England drugs watchdog

Nice says more evidence needed on effectiveness of tirzepatide, sold under brand name Mounjaro

The Guardian - UK

More info needed on weight-loss jab’s impact on type 2 diabetes – Nice

The once-weekly jab would be offered to diabetic patients alongside diet and exercise,

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Investors Business Daily

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

Fortune

How companies can strengthen their workforces in an uncertain labor market

While tech layoffs make splashy headlines, other industries like health care, financial services, and education are eager to scoop up tech workers.

Fortune

Chart of the Day: Eli Lilly - A Retail Investor Favorite

The Chart of the Day belongs to the pharmaceutical company Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stocks Fall on Chinese Economic Concerns and Wariness Ahead of Fed Chair Powell

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.77%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.73%. U.S. stocks this morning are moderately lower. U.S. stocks...

Barchart

Stock Market Claws Back At Midday; AI Robotics Stock Takes A Break

The major indexes trimmed earlier losses in today's stock market. Filtration stock rallies after analysts' coverage and is a recent IPO.

Investors Business Daily

Dice Therapeutics Stock Catapults To Record High On $2.4 Billion Eli Lilly Buyout

Dice stock skyrocketed Tuesday after Eli Lilly pledged to buy the immunology-focused biotech company for $2.4 billion.

Investors Business Daily

Markets Today: Stocks Slip on China Economic Concerns and Higher Bond Yields

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are down -0.33%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are down -0.28%. U.S. stock index futures this morning are moderately lower. Negative carry-over from a decline in Chinese stocks is weighing on U.S. stock index futures on...

Barchart

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million

Eli Lilly inked a gene-editing collaboration with Verve Therapeutics that gave the young biotech "pharma validation."

Investors Business Daily

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Chicago Tribune

Commentary: By avoiding funding Alzheimer’s research, the government is cutting seniors’ life spans

Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer’s medication appears to slow cognitive decline by 35%. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.

Daily Record

New weekly obesity injection could help people rapidly shed body weight

The National Institute for Health and Care Excellence (Nice) is judging whether or not the jab would be a good use of NHS funds.

Wales Online

New once-a week injection helps people lose large amount of weight

The National Institute for Health and Care Excellence (Nice) is seeing whether the drug would be a good use of NHS funds

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

New obesity jab that sparked diabetes row in US could get NHS green light

Tirzepatide is currently approved by regulators for type 2 diabetes – but may soon also be approved for obesity

Investors Business Daily

Eli Lilly Stock Doesn't Have To Shoot Higher For Profits

If Eli Lilly stays around 440, this calendar spread profits on its neutral outlook.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

The Conversation

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The New Daily

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

The New Daily

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

Investors Business Daily

Dow Jones Falls On Peak-Rate Uncertainty; QCOM Falls While ETSY, RUN Rise After Earnings

The Dow Jones rose ahead of a Fed rate hike. Fed Chief Powell's comments suggested a rate pause. Eli Lilly surged after reporting a breakthrough Alzheimer's treatment.

1 … 18 19 20 21

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Warner Bros Discovery

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.